934194
NanoFabTx™- PEG-RGD Lipid Mix
for synthesis of PEGylated RGD-functionalized liposomes
Synonym(s):
Liposome synthesis kit, Small molecule drug formulation kit
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352211
Recommended Products
Quality Level
storage temp.
−20°C
Related Categories
Application
About Targeted NanoFabTx™
Targeted NanoFabTX™- PEG-RGD Lipid Mix; for synthesis of PEGylated RGD targeted liposomes is a ready-to-use nanoformulation lipid blend that includes lyophilized lipids and step-by-step instructions for synthesizing PEG-RGD targeted liposomes for the targeted delivery of the API to cancer cells.
Lipid-based formulations are widely used for drug delivery and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins and peptides. This optimized lipid blend containg RGD peptide for targeted drug delivery and PEG to improve circulation time and impose stealth like behavior.
Application example:
Integrins (alpha V beta 3) are overexpressed by many cancer cells. The RGD peptide has high affinity to the integrins. Thus, liposomes containing the ligand RGD can be used to deliver the anti-cancer agent directly to the cancer cells. The targeted RGD liposomes will deliver the API to only the cancer cells and not the healthy cells. As a result, the targeted liposomes avoid off target effects which is a side effect of many anti-cancer therapies.
Targeted NanoFabTX™- PEG-RGD Lipid Mix; for synthesis of PEGylated RGD targeted liposomes is a ready-to-use nanoformulation lipid blend that includes lyophilized lipids and step-by-step instructions for synthesizing PEG-RGD targeted liposomes for the targeted delivery of the API to cancer cells.
Lipid-based formulations are widely used for drug delivery and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins and peptides. This optimized lipid blend containg RGD peptide for targeted drug delivery and PEG to improve circulation time and impose stealth like behavior.
Application example:
Integrins (alpha V beta 3) are overexpressed by many cancer cells. The RGD peptide has high affinity to the integrins. Thus, liposomes containing the ligand RGD can be used to deliver the anti-cancer agent directly to the cancer cells. The targeted RGD liposomes will deliver the API to only the cancer cells and not the healthy cells. As a result, the targeted liposomes avoid off target effects which is a side effect of many anti-cancer therapies.
Features and Benefits
- A ready-to-use lipid blend for the synthesis of PEG-RGD targeted liposomes.
- Step-by-step protocols (extrusion, microfluidics) developed and tested by our formulation scientists.
- Flexible synthesis tool to create uniform and reproducible liposomes.
- RGD ligand enables targeted drug delivery
- A lipid film hydration and extrusion protocol
- A microfluidics protocol using commercial platforms or syringe pumps
For more information, please refer to the protocol under the Protocol section of this page.
Legal Information
NanoFabTx is a trademark of Sigma-Aldrich Co. LLC
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells
Chen CW, et al.
International journal of nanomedicine, 6, 2567-2580 (2011)
RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer
Wang F, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 196, 222-233 (2014)
Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer
Sheikh A, et al.
Frontiers in Pharmacology, 12, 803304-803304 (2022)
Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies
Tang Z, et al.
Drug design, development and therapy, 13, 3281-3290 (2019)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service